"Antisense Therapeutics Limited (“ANP” or “the Company”) is...

"Antisense Therapeutics Limited (“ANP” or “the Company”) is pleased to announce that the US Food and Drug Administration (FDA) has responded affirm atively to the Company’s plan to submit a U.S. Investigational New Drug (IND) application for initiation of longer term Phase IIb human trials of ATL1102 for the treatment of Multiple Sclerosis (MS). Supportive guidance was obtained from the agency’s Pre-IND assessment of the development strategy for ATL1102, including plans for a Phase IIb study in MS patients." -24 OCTOBER 2014

"The Company intends to submit an IND application for a Phase IIb trial in SP-MS patients. The IND application is in preparation and ANP expects to submit the IND with the Food and Drug Administration (FDA) before end 3’Q’2016." -17 JUNE 2016


"ANP to submit a US IND application in early 2017 for Phase
IIb human trial" -4 JAN 2017


How long did you say your oppies had this time Gassy?